MBX Biosciences (MBX) Total Current Liabilities (2023 - 2026)

MBX Biosciences has disclosed Total Current Liabilities across 4 years of filings, most recently posting $14.6 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $14.6 million, up 38.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.6 million (up 38.98% YoY), and the FY2025 annual result was $15.5 million, up 40.21% from the prior year.
• Total Current Liabilities came in at $14.6 million for Q1 2026 at MBX Biosciences, down from $15.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $15.5 million in Q4 2025 to a low of $3.9 million in Q4 2023.
• The 4-year median for Total Current Liabilities is $11.4 million (2024), against an average of $11.3 million.
• Across the five-year window, Total Current Liabilities surged 181.48% in 2024 and rose 10.46% in 2025, its largest moves.
• MBX Biosciences' Total Current Liabilities stood at $3.9 million in 2023, then soared by 181.48% to $11.1 million in 2024, then jumped by 40.21% to $15.5 million in 2025, then slipped by 5.99% to $14.6 million in 2026.
• The last three Total Current Liabilities figures came in at $14.6 million (Q1 2026), $15.5 million (Q4 2025), and $12.1 million (Q3 2025), per Business Quant data.